Key Points
- Passage Bio CEO William Chou sold 4,076 shares on Jan. 8 at $18.44 each for $75,161.44, reducing his stake by 38.45% to 6,524 shares (≈$120,303).
- Shares opened at $17.91 with a market cap of $56.95M, a negative PE (-1.24), 50‑day/200‑day moving averages of $10.25 and $8.32, and a one‑year range of $5.12–$20.00.
- Analyst coverage is mixed—three Buys and one Sell—with a consensus rating of "Moderate Buy" and a $42.67 consensus price target, while institutional investors own about 53.48% of the stock (Squarepoint added a new stake).
Passage Bio, Inc. (NASDAQ:PASG - Get Free Report) CEO William Chou sold 4,076 shares of Passage Bio stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $18.44, for a total transaction of $75,161.44. Following the completion of the transaction, the chief executive officer owned 6,524 shares in the company, valued at approximately $120,302.56. This trade represents a 38.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Passage Bio Stock Performance
Shares of NASDAQ:PASG opened at $17.91 on Tuesday. The company has a market capitalization of $56.95 million, a PE ratio of -1.24 and a beta of 1.76. The stock has a fifty day moving average of $10.25 and a 200-day moving average of $8.32. Passage Bio, Inc. has a one year low of $5.12 and a one year high of $20.00.
Passage Bio (NASDAQ:PASG - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported ($2.44) EPS for the quarter, beating the consensus estimate of ($2.64) by $0.20. As a group, research analysts forecast that Passage Bio, Inc. will post -1.03 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts have recently commented on PASG shares. Chardan Capital raised their target price on Passage Bio to $21.00 and gave the stock a "buy" rating in a research report on Wednesday, November 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Passage Bio in a research note on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.67.
Check Out Our Latest Report on PASG
Hedge Funds Weigh In On Passage Bio
A hedge fund recently bought a new stake in Passage Bio stock. Squarepoint Ops LLC acquired a new position in shares of Passage Bio, Inc. (NASDAQ:PASG - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 23,500 shares of the company's stock, valued at approximately $188,000. Squarepoint Ops LLC owned approximately 0.74% of Passage Bio at the end of the most recent quarter. Institutional investors and hedge funds own 53.48% of the company's stock.
About Passage Bio
(
Get Free Report)
Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.
The company's lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
